Courtney Ketchum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Courtney Ketchum has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin L. Liechty
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA
5 shared publications - Cheyanne C. Slocum
Department of Pathology & Laboratory Medicine, Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York
5 shared publications - Daniel A. Orringer
Department of Neurosurgery, NYU Langone Health, New York, New York
5 shared publications - David H. Harter
Division of Pediatric Neurosurgery, Department of Neurosurgery, NYU Langone Medical Center, New York, New York, USA
5 shared publications - Eveline Teresa Hidalgo
Division of Pediatric Neurosurgery, Department of Neurosurgery, NYU Langone Health, New York, USA
5 shared publications - George Jour
Department of Pathology, New York University School of Medicine, New York, New York
5 shared publications
Latest Publications
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
List of genes in the fusion panels
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
List of genes in the fusion panels
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
List of genes in the fusion panels
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
List of genes in the fusion panels
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
List of all gene fusions and associated DNA methylation classes and scores
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
List of all gene fusions and associated DNA methylation classes and scores
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
List of all gene fusions and associated DNA methylation classes and scores
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
List of all gene fusions and associated DNA methylation classes and scores
- 23 October 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 22 (1) , 21-28
Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
DNA methylation is an essential molecular assay for central nervous system (CNS) tumor diagnostics. While some fusions define specific brain tumors, others occur across many different diagnoses. We performed a retrospective analysis of 219 primary CNS tumors with whole genome DNA methylation and RNA next-generation sequencing. DNA methylation profiling results were compared with RNAseq detected gene fusions. We detected 105 rare fusions involving 31 driver genes, including 23 fusions previously not implicated in brain tumors. In addition, we identified 6 multi-fusion tumors. Rare fusions and multi-fusion events can impact the diagnostic accuracy of DNA methylation by decreasing confidence in the result, such as BRAF, RAF, or FGFR1 fusions, or result in a complete mismatch, such as NTRK, EWSR1, FGFR, and ALK fusions. Implications: DNA methylation signatures need to be interpreted in the context of pathology and discordant results warrant testing for novel and rare gene fusions.
- 23 October 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 22 (1) , 21-28
Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
DNA methylation is an essential molecular assay for central nervous system (CNS) tumor diagnostics. While some fusions define specific brain tumors, others occur across many different diagnoses. We performed a retrospective analysis of 219 primary CNS tumors with whole genome DNA methylation and RNA next-generation sequencing. DNA methylation profiling results were compared with RNAseq detected gene fusions. We detected 105 rare fusions involving 31 driver genes, including 23 fusions previously not implicated in brain tumors. In addition, we identified 6 multi-fusion tumors. Rare fusions and multi-fusion events can impact the diagnostic accuracy of DNA methylation by decreasing confidence in the result, such as BRAF, RAF, or FGFR1 fusions, or result in a complete mismatch, such as NTRK, EWSR1, FGFR, and ALK fusions. Implications: DNA methylation signatures need to be interpreted in the context of pathology and discordant results warrant testing for novel and rare gene fusions.